Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

ABSTRACT: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who have advanced primary or metastatic solid tumors that have not responded to previous therapy.

DISEASE(S): Extramedullary Plasmacytoma,Prostatic Neoplasms,Leukemia,Multiple Myeloma And Plasma Cell Neoplasm,Prostate Cancer,Small Intestine Cancer,Plasmacytoma,Lymphoma,Intestinal Neoplasms,Neoplasms, Plasma Cell,Multiple Myeloma,Unspecified Adult Solid Tumor, Protocol Specific

PROVIDER: 2004721 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR